Advanced search
Publication Cover
Blood Pressure Volume 12, 2003 - Issue sup1
Submit an article Journal homepage
361
Views
20
CrossRef citations to date
0
Altmetric
Research Article

Evaluation of the Efficacy and Tolerability of Nebivolol versus Lisinopril in the Treatment of Essential Arterial Hypertension: A Randomized, Multicentre, Double-blind Study

ENRICO AGABITI ROSEI Department of Medical and Surgical Sciences University of Brescia
,
DAMIANO RIZZONI Department of Medical and Surgical Sciences University of Brescia
,
SILVIA COMINI Department of Medical and Surgical Sciences University of Brescia
&
GIANLUCA BOARI Department of Medical and Surgical Sciences University of Brescia
Pages 30-35 | Published online: 08 Jul 2009

Citations (20)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

David S. Kountz. (2009) Are Tolerability Concerns a Class Effect of Beta-Blockers in Treating Patients with Hypertension?. Postgraduate Medicine 121:1, pages 14-24.
Read now
David Wojciechowski & Vasilios Papademetriou. (2008) β-blockers in the management of hypertension: focus on nebivolol. Expert Review of Cardiovascular Therapy 6:4, pages 471-479.
Read now
Robert Weiss. (2006) Nebivolol: A Novel Beta-Blocker with Nitric Oxide-Induced Vasodilatation. Vascular Health and Risk Management 2:3, pages 303-308.
Read now
Guido Grassi, Fosca Quarti Trevano, Annalisa Facchini, Torakis Toutouzas, Bernard Chanu & Giuseppe Mancia. (2003) Efficacy and tolerability profile of nebivolol vs atenolol in mild‐to‐moderate essential hypertension: Results of a double‐blind randomized multicentre trial. Blood Pressure 12:sup2, pages 35-40.
Read now

Articles from other publishers (16)

Waleed AlHabeeb, Sanaa Mrabeti & Ahmed Adel Ibrahim Abdelsalam. (2021) Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovascular Drugs and Therapy 36:5, pages 959-971.
Crossref
Vinícius Bocchino Seleme, Gustavo Lenci Marques, Antonio Eduardo Matoso Mendes, Inajara Rotta, Milena Pereira, Emilton Lima Júnior & Claudio L. Pereira da Cunha. (2020) Nebivolol for the Treatment of Essential Systemic Arterial Hypertension: A Systematic Review and Meta-Analysis. American Journal of Cardiovascular Drugs 21:2, pages 165-180.
Crossref
T. Yu. Demidova & O. A. Kislyak. (2020) The Peculiarity of Process and Treatment of Arterial Hypertension in Patients with Type 2 Diabetes Mellitus. Rational Pharmacotherapy in Cardiology 16:4, pages 623-634.
Crossref
Kyle J. DiehlBrian L. StaufferCaitlin A. DowTyler D. BammertDanielle L. BrunjesJared J. GreinerChristopher A. DeSouza. (2016) Chronic Nebivolol Treatment Suppresses Endothelin-1–Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure. Hypertension 67:6, pages 1196-1204.
Crossref
Cheol-Ho Kim, Nelson Abelardo, Peera Buranakitjaroen, Rungroj Krittayaphong, Chin Hock Lim, Sung-Ha Park, Nguyen Vinh Pham, Gregorio Rogelio, Bernard Wong & Lip Ping Low. (2016) Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol. Heart Asia 8:1, pages 22-26.
Crossref
C. Venkata S. Ram. (2010) Beta-Blockers in Hypertension. The American Journal of Cardiology 106:12, pages 1819-1825.
Crossref
Katherine C. WuGary Gerstenblith. (2010) Review: Update on Newer Antihypertensive Medicines and Interventions. Journal of Cardiovascular Pharmacology and Therapeutics 15:3, pages 257-267.
Crossref
Otto Kamp, Marco Metra, Silvia Bugatti, Luca Bettari, Alessandra Dei Cas, Natalia Petrini & Livio Dei Cas. (2010) Nebivolol. Drugs 70:1, pages 41-56.
Crossref
Jan Basile. (2009) Blood pressure responder rates versus goal rates: which metric matters?. Therapeutic Advances in Cardiovascular Disease 3:2, pages 157-174.
Crossref
Judy W.M. Cheng. (2009) Nebivolol: A third-generation β-blocker for hypertension. Clinical Therapeutics 31:3, pages 447-462.
Crossref
L G Ratova & I E Chazova. (2008) b-Adrenoblokator s unikal'nymi kharakteristikami - nebivolol. Systemic Hypertension 5:3, pages 55-58.
Crossref
William C. Roberts, Henry R. Black, George L. Bakris, R. Preston Mason, Thomas D. Giles & Destry J. Sulkes. (2007) The Editor’s Roundtable: Revisiting the Role of Beta Blockers in Hypertension. The American Journal of Cardiology 100:2, pages 253-267.
Crossref
Zafar H Israili, Rafael Hernández-Hernández & Manuel Valasco. (2007) The Future of Antihypertensive Treatment. American Journal of Therapeutics 14:2, pages 121-134.
Crossref
Enrico Agabiti Rosei & Damiano Rizzoni. (2007) Metabolic Profile of Nebivolol, a ??-Adrenoceptor Antagonist with Unique Characteristics. Drugs 67:8, pages 1097-1107.
Crossref
Sachin S. Sule & William Frishman. (2006) Nebivolol. Cardiology in Review 14:5, pages 259-264.
Crossref
Angie Veverka, Donald S Nuzum & Jamie L Jolly. (2016) Nebivolol: A Third-Generation β-Adrenergic Blocker. Annals of Pharmacotherapy 40:7-8, pages 1353-1360.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.